GRI

GRI Bio

• Dow Jones·08/24 09:54

  GRI Bio Is Maintained at Buy by Ascendiant Capital

• Dow Jones·08/24 09:54

  GRI Bio Price Target Cut to $27.00/Share From $32.00 by Ascendiant Capital

• TipRanks·06/18 23:11

  GRI Bio Secures FDA Orphan Drug Status for IPF

• TipRanks·06/18 13:05

  GRI Bio announces U.S. FDA granted ODD to GRI-0621

• TipRanks·06/17 15:00

  GRI Bio granted FDA orphan designation for tazarotene

• TipRanks·06/03 12:44

  GRI Bio (GRI) Gets a Buy from Ascendiant

• Dow Jones·06/01 10:38

  GRI Bio Is Maintained at Buy by Ascendiant Capital

• Dow Jones·06/01 10:38

  GRI Bio Price Target Cut to $32.00/Share From $40.00 by Ascendiant Capital

• Seeking Alpha·05/14 18:31

  GRI Bio reports Q1 results

• TipRanks·05/14 13:02

  GRI Bio Highlights Promising Phase 2a IPF Data, Outlook

• TipRanks·05/14 10:40

  Analysts’ Top Healthcare Picks: GRI Bio (GRI), Ovid Therapeutics (OVID)

• TipRanks·04/08 13:21

  GRI Bio receives UAE patent allowance for inflammatory disease treatments

• Dow Jones·03/11 12:52

  GRI Bio Is Maintained at Buy by Ascendiant Capital

• Dow Jones·03/11 12:52

  GRI Bio Price Target Cut to $40.00/Share From $1008.00 by Ascendiant Capital

• TipRanks·03/06 11:30

  Analysts Are Bullish on These Healthcare Stocks: Cooper Co (COO), Pelthos Therapeutics (PTHS)